The biotech variety show continues. The jokers at Morgan Stanley upgraded BLUE on 10/5, affixing a price target of $143 to it. Tonight, after some hard data was revealed, that showed BLUE to be nothing more than a devlopmental piece of shit, the spazzes at MS downgraded them in a mea culpa report, slashing the target to a clowish $69.
Why $69?
Because everyone gets fucked that way.
Why bother posting more? All drivel.
Stick to names like AMGN, GILD and EW– avoid the glorified research labs like the plague.
If you enjoy the content at iBankCoin, please follow us on Twitter

BAML also moved their rating this am to neutral (non stellar data for BB305 in SCD) with PO to $102 from $149. Outright giddy versus MS price target. JCG